Maintenance therapy after first treatment for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV).
- Your first chemotherapy treatment was effective, and you have either no sign of cancer or a significant reduction in tumor size.
- You start the study medications within 9 weeks after your last chemotherapy dose.
- You have not had prior treatment with a PARP inhibitor or certain other targeted therapies (except bevacizumab).
- You have adequate organ function and can swallow oral medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
This trial tests whether adding fluzoparib to bevacizumab can help control ovarian cancer that has returned after earlier PARP inhibitor (PARPi) treatment. It may help shrink tumors or slow the cancer from growing again.
This trial tests two oral drugs, fluzoparib and dalpiciclib, given together, for ovarian cancer that has returned or progressed shortly after platinum chemotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.